Two Sigma Advisers’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2M | Sell |
1,767,400
-433,400
| -20% | -$490K | ﹤0.01% | 1120 |
|
|
2025
Q1 | $3.21M | Sell |
2,200,800
-501,400
| -19% | -$732K | 0.01% | 966 |
|
|
2024
Q4 | $5.76M | Buy |
2,702,200
+291,800
| +12% | +$622K | 0.01% | 665 |
|
|
2024
Q3 | $6.75M | Buy |
2,410,400
+167,900
| +7% | +$470K | 0.02% | 607 |
|
|
2024
Q2 | $5.23M | Buy |
2,242,500
+911,400
| +68% | +$2.12M | 0.01% | 739 |
|
|
2024
Q1 | $5.95M | Buy |
1,331,100
+53,400
| +4% | +$239K | 0.01% | 709 |
|
|
2023
Q4 | $4.1M | Buy |
1,277,700
+300,500
| +31% | +$965K | 0.01% | 902 |
|
|
2023
Q3 | $3.1M | Sell |
977,200
-237,500
| -20% | -$753K | 0.01% | 966 |
|
|
2023
Q2 | $6.04M | Sell |
1,214,700
-80,100
| -6% | -$398K | 0.02% | 682 |
|
|
2023
Q1 | $6.4M | Buy |
1,294,800
+334,400
| +35% | +$1.65M | 0.02% | 713 |
|
|
2022
Q4 | $6.04M | Buy |
960,400
+737,900
| +332% | +$4.64M | 0.02% | 706 |
|
|
2022
Q3 | $2.4M | Buy |
222,500
+90,000
| +68% | +$972K | 0.01% | 1076 |
|
|
2022
Q2 | $1.51M | Sell |
132,500
-100,000
| -43% | -$1.14M | ﹤0.01% | 1370 |
|
|
2022
Q1 | $2.12M | Buy |
+232,500
| New | +$2.12M | 0.01% | 1226 |
|
|
2021
Q3 | – | Sell |
-67,800
| Closed | -$1.77M | – | 2426 |
|
|
2021
Q2 | $1.77M | Sell |
67,800
-346,300
| -84% | -$9.03M | ﹤0.01% | 1350 |
|
|
2021
Q1 | $14.6M | Buy |
414,100
+62,300
| +18% | +$2.2M | 0.04% | 438 |
|
|
2020
Q4 | $8.88M | Buy |
351,800
+14,300
| +4% | +$361K | 0.02% | 607 |
|
|
2020
Q3 | $12.7M | Buy |
337,500
+305,300
| +948% | +$11.5M | 0.04% | 461 |
|
|
2020
Q2 | $1.38M | Buy |
+32,200
| New | +$1.38M | ﹤0.01% | 1415 |
|